drugset / Trial / NCT00038922

Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

NCT00038922

Treatment

Summary

To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject rhIL-11 Protein / enzyme biologic Oral

Indications